Report an error

Spotted something inaccurate in “PARP inhibitor niraparib doubles progression-free survival in BRCA-positive prostate cancer”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.